Frontier Biotechnologies Inc. (688221)
SSE SSE Primary Summary
688221 Chart
People also search for
Frontier Biotechnologies Inc. (688221) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Frontier Biotechnologies Inc. ever had a stock split?
Frontier Biotechnologies Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Qi Shao CEO | SSE Exchange | - ISIN |
| CN Country | 395 Employees | - Last Dividend | 24 Jul 2000 Last Split | - IPO Date |
Overview
Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical entity dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines designed to enhance patient health. Established in 2013 and based in Nanjing, China, the company focuses on addressing the unmet medical needs in anti-HIV treatment and pain management. Through its commitment to research and development, Frontier Biotechnologies aims to bring transformative medical solutions to patients worldwide, contributing significantly to the fields of HIV infection, AIDS, COVID-19 prophylaxis and treatment, and chronic pain management.
Products and Services
- Aikening
- FB1002
- FB2001
- FB3001
- FB600
A long-acting HIV fusion inhibitor, Aikening represents a ground-breaking treatment for patients with HIV infection and AIDS. This medication provides a much-needed option for those requiring durable suppression of the viral load, improving patient outcomes and quality of life.
In development, FB1002 is an all-injectable long-acting therapy aimed at providing an innovative treatment solution for HIV. This product underscores the company's ongoing commitment to evolving the HIV treatment landscape with more convenient and effective options.
Currently under clinical development, FB2001 is a SARS-CoV-2 3CL protease inhibitor targeting hospitalized patients and also intended for post-exposure prophylaxis of Covid-19. This reflects Frontier Biotechnologies' rapid response to global health crises and its dedication to leveraging its platform to address emergent health threats.
Addressing the substantial need for effective pain management solutions, FB3001 is a novel transdermal topical patch under clinical development for the treatment of musculoskeletal joint pain. This innovative approach aims to provide patients with a non-invasive, effective option for managing chronic pain, enhancing patient adherence and lifestyle.
An investigational therapeutic peptide vaccine, FB600 targets PCSK9 to treat hypercholesterolemia. Still in the investigational phase, this product represents a novel approach to managing cholesterol levels, potentially lowering the risk of cardiovascular diseases significantly.
